{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T07:18:09Z","timestamp":1790839089475,"version":"4.1.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.revmed.2024.10.006","type":"journal-article","created":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T22:43:36Z","timestamp":1730760216000},"page":"4-11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Use of immunosuppressants and biologics in giant cell arteritis: Recommendations of the French Study Group for Large Vessel Vasculitis (GEFA)"],"prefix":"10.1016","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9083-8365","authenticated-orcid":false,"given":"Hubert","family":"de Boysson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Devauchelle-Pensec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Agard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9008-701X","authenticated-orcid":false,"given":"Marc","family":"Andr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Bienvenu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7229-3808","authenticated-orcid":false,"given":"Bernard","family":"Bonnotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5281-5445","authenticated-orcid":false,"given":"Guillermo","family":"Carvajal Alegria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Espitia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Hachulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"H\u00e9ron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Christophe","family":"Lega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8511-903X","authenticated-orcid":false,"given":"Kim H.","family":"Ly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ars\u00e8ne","family":"Mekinian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Morel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"R\u00e9gent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3029-8739","authenticated-orcid":false,"given":"Christophe","family":"Richez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Sailler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphaele","family":"Seror","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Tournadre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6547-232X","authenticated-orcid":false,"given":"Maxime","family":"Samson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.revmed.2024.10.006_bib0235","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S0140-6736(08)61077-6","article-title":"Polymyalgia rheumatica and giant-cell arteritis","volume":"372","author":"Salvarani","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.revmed.2024.10.006_bib0240","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1002\/art.23577","article-title":"Aortic involvement in recent-onset giant cell (temporal) arteritis: a case-control prospective study using helical aortic computed tomodensitometric scan","volume":"59","author":"Agard","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2024.10.006_bib0245","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1093\/rheumatology\/keu329","article-title":"Large-vessel giant cell arteritis: a cohort study","volume":"54","author":"Muratore","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.revmed.2024.10.006_bib0250","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1136\/annrheumdis-2011-200865","article-title":"Large vessel involvement in biopsy-proven giant cell arteritis: prospective study in 40 newly diagnosed patients using CT angiography","volume":"71","author":"Prieto-Gonzalez","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2024.10.006_bib0255","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1136\/annrheumdis-2013-204572","article-title":"Positron emission tomography assessment of large vessel inflammation in patients with newly diagnosed, biopsy-proven giant cell arteritis: a prospective, case-control study","volume":"73","author":"Prieto-Gonzalez","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2024.10.006_bib0260","doi-asserted-by":"crossref","first-page":"102283","DOI":"10.1016\/j.jaut.2019.05.011","article-title":"Different patterns and specific outcomes of large-vessel involvements in giant cell arteritis","volume":"103","author":"de Boysson","year":"2019","journal-title":"J Autoimmun"},{"key":"10.1016\/j.revmed.2024.10.006_bib0265","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3899\/jrheum.181127","article-title":"Factors associated with relapse and dependence on glucocorticoids in giant cell arteritis","volume":"47","author":"Dumont","year":"2020","journal-title":"J Rheumatol"},{"key":"10.1016\/j.revmed.2024.10.006_bib0270","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.7326\/M23-0679","article-title":"Association between vascular (18)F-Fluorodeoxyglucose uptake at diagnosis and change in aortic dimensions in giant cell arteritis: a cohort study","volume":"176","author":"Moreel","year":"2023","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.revmed.2024.10.006_bib0275","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.3899\/jrheum.120511","article-title":"Giant cell arteritis with or without aortitis at diagnosis. A retrospective study of 22 patients with long-term follow-up","volume":"39","author":"Espitia","year":"2012","journal-title":"J Rheumatol"},{"key":"10.1016\/j.revmed.2024.10.006_bib0280","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.revmed.2015.12.015","article-title":"Management of giant cell arteritis: recommendations of the French Study Group for Large Vessel Vasculitis (GEFA)","volume":"37","author":"Bienvenu","year":"2016","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.revmed.2024.10.006_bib0285","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/annrheumdis-2019-215672","article-title":"2018 Update of the EULAR recommendations for the management of large vessel vasculitis","volume":"79","author":"Hellmich","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2024.10.006_bib0290","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/acr.23901","article-title":"Prevalence of giant cell arteritis relapse in patients treated with glucocorticoids: a meta-analysis","volume":"72","author":"Mainbourg","year":"2020","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.revmed.2024.10.006_bib0295","doi-asserted-by":"crossref","first-page":"ii11","DOI":"10.1093\/rheumatology\/kex459","article-title":"Prevention of glucocorticoid morbidity in giant cell arteritis","volume":"57","author":"Buttgereit","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.revmed.2024.10.006_bib0300","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.3390\/jcm11041034","article-title":"Impact of glucocorticoid cumulative doses in a real-life cohort of patients affected by giant cell arteritis","volume":"1","author":"Castan","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.revmed.2024.10.006_bib0305","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/art.11388","article-title":"Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes","volume":"49","author":"Proven","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2024.10.006_bib0310","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1613849","article-title":"Trial of tocilizumab in giant-cell arteritis","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2024.10.006_bib0315","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1002\/art.41774","article-title":"2021 American College of Rheumatology\/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis","volume":"73","author":"Maz","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.revmed.2024.10.006_bib0320","doi-asserted-by":"crossref","first-page":"3567","DOI":"10.1093\/rheumatology\/keab921","article-title":"Tolerance of glucocorticoids in giant cell arteritis: a study of patient-reported adverse events","volume":"61","author":"de Boysson","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.revmed.2024.10.006_bib0330","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S2665-9913(21)00038-2","article-title":"Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the Giant Cell Arteritis Actemra (GiACTA) trial","volume":"3","author":"Stone","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.revmed.2024.10.006_bib0335","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1002\/art.10262","article-title":"A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis","volume":"46","author":"Hoffman","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2024.10.006_bib0340","doi-asserted-by":"crossref","first-page":"106","DOI":"10.7326\/0003-4819-134-2-200101160-00010","article-title":"Combined treatment of giant-cell arteritis with methotrexate and prednisone. A randomized, double-blind, placebo-controlled trial","volume":"134","author":"Jover","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.revmed.2024.10.006_bib0345","first-page":"495","article-title":"A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA)","volume":"19","author":"Spiera","year":"2001","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.revmed.2024.10.006_bib0350","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1002\/art.22754","article-title":"Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis","volume":"56","author":"Mahr","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2024.10.006_bib0355","doi-asserted-by":"crossref","first-page":"e341","DOI":"10.1016\/S2665-9913(23)00101-7","article-title":"Safety and efficacy of secukinumab in patients with giant cell arteritis (TitAIN): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"5","author":"Venhoff","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.revmed.2024.10.006_bib0360","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1136\/annrheumdis-2021-221961","article-title":"Baricitinib for relapsing giant cell arteritis: a prospective open-label 52-week pilot study","volume":"81","author":"Koster","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2024.10.006_bib0365","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.semarthrit.2018.04.004","article-title":"Ustekinumab for refractory giant cell arteritis: a prospective 52-week trial","volume":"48","author":"Conway","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.revmed.2024.10.006_bib0370","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1002\/acr.24200","article-title":"Ustekinumab for the treatment of giant cell arteritis","volume":"73","author":"Matza","year":"2021","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.revmed.2024.10.006_bib0375","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/art.40044","article-title":"A randomized, double-blind trial of abatacept (CTLA-4Ig) for the treatment of giant cell arteritis","volume":"69","author":"Langford","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.revmed.2024.10.006_bib0380","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1136\/annrheumdis-2021-221865","article-title":"Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial","volume":"81","author":"Cid","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2024.10.006_bib0385","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/s41584-020-0370-z","article-title":"Views on glucocorticoid therapy in rheumatology: the age of convergence","volume":"16","author":"Buttgereit","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.revmed.2024.10.006_bib0390","first-page":"S98","article-title":"Glucocorticoid usage in giant cell arteritis over six decades (1950 to 2009)","volume":"33","author":"Chandran","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.revmed.2024.10.006_bib0395","doi-asserted-by":"crossref","first-page":"e1003432","DOI":"10.1371\/journal.pmed.1003432","article-title":"Dose-dependent oral glucocorticoid cardiovascular risks in people with immune-mediated inflammatory diseases: a population-based cohort study","volume":"17","author":"Pujades-Rodriguez","year":"2020","journal-title":"PLoS Med"},{"key":"10.1016\/j.revmed.2024.10.006_bib0400","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.semarthrit.2016.11.006","article-title":"Serious adverse effects associated with glucocorticoid therapy in patients with giant cell arteritis (GCA): a nested case-control analysis","volume":"46","author":"Wilson","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.revmed.2024.10.006_bib0405","doi-asserted-by":"crossref","first-page":"4384","DOI":"10.1093\/rheumatology\/keaa894","article-title":"Use of 18F-fluorodeoxyglucose positron emission tomography to monitor tocilizumab effect on vascular inflammation in giant cell arteritis","volume":"60","author":"Quinn","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.revmed.2024.10.006_bib0410","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1093\/rheumatology\/key015","article-title":"Magnetic resonance angiography in giant cell arteritis: results of a randomized controlled trial of tocilizumab in giant cell arteritis","volume":"57","author":"Reichenbach","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.revmed.2024.10.006_bib0415","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.semarthrit.2021.01.006","article-title":"Tocilizumab in refractory giant cell arteritis. Monotherapy versus combined therapy with conventional immunosuppressive drugs. Observational multicenter study of 134 patients","volume":"51","author":"Calderon-Goercke","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.revmed.2024.10.006_bib0420","doi-asserted-by":"crossref","first-page":"e619","DOI":"10.1016\/S2665-9913(21)00152-1","article-title":"Tocilizumab monotherapy after ultra-short glucocorticoid administration in giant cell arteritis: a single-arm, open-label, proof-of-concept study","volume":"3","author":"Christ","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.revmed.2024.10.006_bib0425","doi-asserted-by":"crossref","first-page":"105220","DOI":"10.1016\/j.jbspin.2021.105220","article-title":"Practical management of patients on anti-IL6R therapy\u00a0\u2013\u00a0the CRI guidelines","volume":"88","author":"Morel","year":"2021","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.revmed.2024.10.006_bib0430","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ejim.2018.06.008","article-title":"Tocilizumab as an add-on therapy to glucocorticoids during the first 3 months of treatment of Giant cell arteritis: a prospective study","volume":"57","author":"Samson","year":"2018","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.revmed.2024.10.006_bib0435","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1016\/S0140-6736(16)00560-2","article-title":"Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial","volume":"387","author":"Villiger","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.revmed.2024.10.006_bib0440","doi-asserted-by":"crossref","first-page":"152174","DOI":"10.1016\/j.semarthrit.2023.152174","article-title":"Effectiveness of a two-year tapered course of tocilizumab in patients with giant cell arteritis: a single-centre prospective study","volume":"59","author":"Tomelleri","year":"2023","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.revmed.2024.10.006_bib0445","article-title":"Relapse after cessation of weekly tocilizumab for giant cell arteritis: a multicentre service evaluation in England","author":"Quick","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.revmed.2024.10.006_bib0450","doi-asserted-by":"crossref","first-page":"152192","DOI":"10.1016\/j.semarthrit.2023.152192","article-title":"Efficacy and tolerance of methotrexate in a real-life monocentric cohort of patients with giant cell arteritis","volume":"60","author":"Lavergne","year":"2023","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.revmed.2024.10.006_bib0455","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3899\/jrheum.180429","article-title":"Efficacy of methotrexate in real-world management of giant cell arteritis: a case-control study","volume":"46","author":"Koster","year":"2019","journal-title":"J Rheumatol"},{"key":"10.1016\/j.revmed.2024.10.006_bib0460","doi-asserted-by":"crossref","first-page":"e736","DOI":"10.1016\/S2665-9913(23)00265-5","article-title":"Treatment for giant cell arteritis with 8 weeks of prednisone in combination with tocilizumab: a single-arm, open-label, proof-of-concept study","volume":"5","author":"Unizony","year":"2023","journal-title":"Lancet Rheumatol"}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866324008051?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866324008051?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T13:01:52Z","timestamp":1736427712000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0248866324008051"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S0248866324008051"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2024.10.006","relation":{},"ISSN":["0248-8663"],"issn-type":[{"value":"0248-8663","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of immunosuppressants and biologics in giant cell arteritis: Recommendations of the French Study Group for Large Vessel Vasculitis (GEFA)","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2024.10.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Soci\u00e9t\u00e9 Nationale Fran\u00e7aise de M\u00e9decine Interne (SNFMI). Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}